Wegobi, the dream obesity medicine, was released in Korea from the 15th.
Obesity treatment WeGobee (AP Yonhap News)
Since the first day of its launch, prescription inquiries have been flooding in at obesity clinics and plastic surgery clinics, leading to shortages from the start. Due to a global shortage, domestic supply will not be sufficient for some time, so hospitals and clinics are expected to make every effort to secure the initial supply.
WeGobee became even more famous after world-renowned entrepreneur Elon Musk mentioned that WeGoBe and intermittent fasting had a significant influence on his process of losing 14 kg.
In particular, in countries like the United States where 4 out of 10 adults are obese, WeGobee, which is highly effective, is bound to gain sensational popularity and is rapidly changing the obesity and diet market.
Elon Musk changed after taking Wivigo (JoongAng Ilbo)
Wegobee was developed by Novo Nordisk, a large Danish global healthcare and pharmaceutical company founded in 1925.
Novo Nordisk’s recent stock market capitalization is approximately KRW 550 trillion, ranking first in Europe, ahead of Louis Vuitton (LVMH).achieved.
It is larger than the GDP of Denmark, the country where the headquarters is located, and is far ahead of Samsung Electronics, the number one company in Korea, with KRW 355 trillion. To this extent, the capital market is showing the future of how much the future healthcare market will grow.
Obesity is no longer just a matter of appearance and beauty. It is the fundamental cause of various diseases and adult diseases. It is also serving as a backdrop for the continued growth of the healthcare market.
As the healthcare market is growing, surprising changes are occurring in the market with the launch of obesity medications as a game changer.
The diet industry, which started with the aerobics craze in the 1980s, evolved with the Fourth Industrial Revolution and developed into a weight management method through smartphone apps, and has expanded further after COVID-19, occupying an important position in the digital healthcare field.
However, recently, the diet industry as well as healthcare apps that help with dieting have begun to face a crisis. In addition, food-related industries are also exposed to many risks. The reason is the launch of effective obesity drugs.
Wigobi acts on a hormone called GLP-1 (Glucagon-like peptide-1) in the human body, stimulating insulin secretion and increasing satiety. Since it is a principle that reduces hunger and induces weight loss, it is expected to have a significant impact on the food industry in the future.
Changes in consumption by eating out group after taking medication (Morgan Stanley website)
According to a report by investment bank Morgan Stanley, a survey of 300 consumers taking GLP-1 found that many of them showed changes in food intake and spending in the early stages of weight loss.
63% of participants showed a decrease in eating out spending after taking GLP-1. It is said that 61% of people also reduced their use of delivery food. 31% of respondents said they had reduced their total grocery spending compared to before taking GLP-1.
In particular, demand for unhealthy foods and high-fat, high-protein and high-salt options could be significantly reduced.
GLP-1 also affected the pattern of food consumption.
86% of respondents answered that they consumed less food when eating out. Considering that GLP-1’s greatest efficacy is appetite suppression, it is a natural result and seems to be a response that can predict the future.
Changes in consumption by food category after taking medication (Morgan Stanley website)
It also affected the consumption of alcohol and carbonated drinks, with 50% of respondents saying they reduced their consumption of alcohol, carbonated drinks, and salty snacks such as snacks by more than 50%, and 20% said they had stopped drinking alcohol altogether.
especially, Foods high in sugar and fat were reduced the most, while consumption of sweets, beverages, and baked goods was reduced by up to two-thirds. It is expected that there will be major changes in the industries of ice cream, carbonated drinks, cakes, confectionery, chocolate, and frozen pizza in the future. In fact, after the introduction of Wegobee, the stock price of Nestle, the world’s number one food company, fell by about 23%.
In conclusion, in a country that has entered a shrinking society with a declining population, the effective expansion of obesity will act as a major risk to the food and restaurant industry in the mid to long term.
However, if we break away from the existing image of instant food and enter the care food market in earnest, new opportunities will open up.
As mentioned earlier, the healthcare market is receiving more attention and expanding in size as the country becomes more advanced. At the center of this, care food will play a big role and open a new future era.
Controlling it through medication has limitations in terms of side effects and satisfying the pleasure of eating.
existing Beyond therapeutic food, we provide balanced nutrition in connection with food technology such as big data and 3D printing, and provide customized diets by systematically analyzing the nutritional status of consumers.If we do this, Care Food will open a surprising future market like Webigo. In particular, infinite market growth is expected in the adult disease prevention and diet sectors.
The next article is care food that goes beyond therapeutic food and expands to adult diseases and diet! no see.
